FindTrial
Sign In

INVESTIGATION OF THE EFFECT OF GUT BACTERIA ON MARKERS OF INFLAMMATION IN PATIENTS OF HIGH CHOLESTEROL WHO TAKING STATIN DRUGS AS TREATMENT

TO INVESTIGATE THE INFLUENCE OF GUT MICROBIOTA COMPOSITION ON INFLAMMATORY MARKERS IN HYPERCHOLESTEROLEMIC SUBJECTS ON STATIN THERAPY - MIST

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/09/015689
Enrollment
20
Registered
2018-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: -

Interventions

Control Intervention1: Statin drug therapy: Statin will be administered orally at bedtime and dose of statin will be as follows: Group 1: Patients of Hypercholesterolemia receiving Moderate Dose (10

Sponsors

ARDU RUHS College of Health Sciences Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Confirmed cases of Hypercholesterolemia, defined as having the following: LDL >130 mg/dl, total cholesterol >200 mg/dl, HDL

Exclusion criteria

Exclusion criteria: 1. Use of lipid-lowering drugs 2. Patients of Acute and Chronic infections 3. Overt Nephropathy 4. Use of antibiotics, antifungals, antivirals and antiparasitics drugs

Design outcomes

Primary

MeasureTime frame
To examine association between gut microbiome and inflammation at different doses of statin.Timepoint: 12 weeks—

Secondary

MeasureTime frame
To compare the effect of high and low dose of statin on inflammatory markers. Timepoint: 12 weeks—

Countries

India

Contacts

Public ContactDr Priyanka Jain

RUHS College of Medical Sciences, Jaipur

sonalisharma14@gmail.com9414314678

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026